OPALE Model: Adult Height Prediction in Congenital Adrenal Hyperplasia

Sponsor
Hospices Civils de Lyon (Other)
Overall Status
Completed
CT.gov ID
NCT03162159
Collaborator
(none)
496
1
100
5

Study Details

Study Description

Brief Summary

Congenital Adrenal Hyperplasia (CAH) is a genetic rare disease, which alters the adrenal production of gluco and mineralo corticoïds. The treatment consists in supplementing children with hydrocortisone. Despite care for these children has improved substantially across decades, short adult height (AH) still remains an important consequence of the disease. About 20% of patients have an AH below 2 standard deviations compared to their expected AH.

In the OPALE-Model study, the investigators want to collect data from a cohort of 496 CAH French patients, born between 1970 and 1991 with a known genotype. Using their age, sex, growth, disease, bone maturation and pubertal data, the investigators will build a model which allows to predict their AH using data available at 8 years of age. The growth charts built from this cohort have shown that currently used formula to calculate the predicted AH (Bayley-Pineau's formula) is not applicable to children with CAH.

In this project, the investigators plan to compute an AH prediction model using data from children born between 1970 and 1993, and to validate the model using data from a different cohort (i.e. children born between 1994 and 1998). this choice was due to availability of data for computing the model first, and in a second stage, data from more recently born patients.

Condition or Disease Intervention/Treatment Phase
  • Other: Collection of growth and bone maturation data

Study Design

Study Type:
Observational
Actual Enrollment :
496 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
An Adult Height Prediction Model for Congenital Adrenal Hyperplasia From a National Cohort (OPALE Model Study)
Actual Study Start Date :
Sep 1, 2010
Actual Primary Completion Date :
Dec 31, 2018
Actual Study Completion Date :
Dec 31, 2018

Arms and Interventions

Arm Intervention/Treatment
cohort for model computing

patients with CAH, born between 1970 and 1993, with genetically proven CAH, available growth and bone maturation data.

Other: Collection of growth and bone maturation data

cohort for model validation

patients with CAH, born between 1994 and 1998, with genetically proven CAH, available growth and bone maturation data.

Other: Collection of growth and bone maturation data

Outcome Measures

Primary Outcome Measures

  1. Adult height (AH) [up to 18 years]

    AH is defined as i) the height recorded after age 20 in boys or 18 in girls; ii) Or the height recorded when bone age is >= 18 years in boys and 16 years in girls; Or iii) the height measured after growth velocity dropped to <= 1 cm/year.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 40 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • children with CAH, genetically proven, classical form, virilizing form, with deficit of 21 hydroxylase, 11 beta hydroxylase, or 3 beta ol dehydrogenase, born between 1972-1993 (cohort 1) and 1994-1998 (cohort 2).

  • medical charts should be available.

Exclusion Criteria:
  • Patients with chronic growth altering disease, Turner syndrome, or other genetic anomaly

  • Patients having received any treatment with Growth Hormone (GH)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hospices Civils de Lyon Lyon France 69500

Sponsors and Collaborators

  • Hospices Civils de Lyon

Investigators

  • Study Chair: Catherine Cornu, MD, Hospices Civils de Lyon

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Hospices Civils de Lyon
ClinicalTrials.gov Identifier:
NCT03162159
Other Study ID Numbers:
  • CE-CIC-GREN-09-19
First Posted:
May 22, 2017
Last Update Posted:
Aug 11, 2020
Last Verified:
Aug 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 11, 2020